Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol

• Autores: Anita Slomski
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 20, 2017, págs. 2054-2054
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In a trial published recently in the New England Journal of Medicine (NEJM), evolocumab, a monoclonal antibody that inhibits circulating PCSK9 (proprotein convertase subtilisin-kexin type 9) by preventing it from binding to the low-density lipoprotein (LDL) receptor, was found to reduce LDL cholesterol and cardiovascular risk in patients with elevated cholesterol despite high-intensity statin therapy.